Givlaari (Givosiran)
- Medicine Name: Givlaari
- Generic Name: Givosiran
- Dosage Form & Strength: Injection: 189 mg/mL in a single-dose vial
- Manufactured By: Alnylam Pharmaceuticals, Inc.
Givlaari is an aminolevulinate synthase 1-directed small interfering RNA used for the treatment of adults with acute hepatic porphyria (AHP).
Recommended Dosage: The recommended dose is 2.5 mg/kg administered via subcutaneous injection once monthly. Dosing is typically based on actual body weight.
Administer givlaari injection as soon as possible following a missed dose. Resume dosing with Givlaari at monthly intervals after administration of the missed dose.
- Use of Givosiran is restricted in patients with known severe hypersensitivity to this medicinal product. Reactions have included anaphylaxis.
- Anaphylaxis may occur with Givlaari treatment. Monitor for signs/symptoms of anaphylaxis. In case anaphylaxis occurs, promptly discontinue administration of Givlaari 189 mg and institute apt medical treatment.
- Transaminase elevations (ALT) of at least 3 times the upper limit of normal (ULN) may emerge in patients treated with Givosiran. Measure liver function tests before starting treatment with Givosiran, repeat every month during the initial 6 months of therapy.
- Increases in the level of serum creatinine and decreases in estimated glomerular filtration rate (eGFR) have been noted during treatment with Givosiran. Monitor renal function during therapy with Givosiran 189 mg.
- Measure the levels of blood homocysteine before starting treatment and monitor for changes while on therapy with Givosiran. In patients with elevated blood homocysteine levels, evaluate folate, vitamins B6 and B12. Consider therapy with a supplement containing vitamin B6 (as monotherapy or a multivitamin preparation).
What documents are required to import GIVLAARI to India?
GIVLAARI (Givosiran Injection) can be imported by patients or government hospitals on the name of the patients only.
The following documentation required to import the product:
- Valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patients Identity Proof (issued by government of India)
How does order be confirmed?
The order will be confirmed only after the receipt of:
- Valid prescription of Doctor
- Import permit if applicable
Is GIVLAARI available in India?
GIVLAARI (givosiran injection) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is facilitator providing input
- On availability of Givlaari in India (Ahmedabad, Mumbai, Kolkata, Hyderabad, Chennai, Delhi, Bangalore and Pune etc.)
- Medicine Price.
- Finding Genuine and reliable source from Canada, Europe, USA and Australia
- Ensuring 100% transparency.
GIVLAARI can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.
IPN (Indian Pharma Network) can facilitate the supply of GIVLAARI (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)
Please contact +91-9310090915 | Toll-Free No: 1800-889-1064 or write us at info@indianpharmanetwork.in for givlaari injection price in India.
We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis. CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis.